Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Veritas In Silico Inc. ( (JP:130A) ) has issued an update.
Veritas In Silico has filed a substance patent application in Japan for a first-in-class antisense nucleic acid drug targeting the p53 gene to prevent ischemic acute kidney injury following cardiovascular surgery, initially focusing on high-risk patients aged 65 and older and projecting potential annual domestic revenue of about ¥15 billion. The candidate ASO, designed to inhibit p53-driven apoptosis in renal cells, is reported to show higher activity than a competing siRNA drug under development, and, in combination with the company’s patented “Perfusio” drug delivery system and cost-reduction strategies for nucleic acid manufacturing, is positioned as a key pillar in VIS’s long-term plan to expand indications, pursue global markets, and strengthen its competitive edge in the fast-growing nucleic acid drug segment.
More about Veritas In Silico Inc.
Veritas In Silico Inc., listed on the TSE Growth market, is a drug discovery company specializing in mRNA-targeted therapeutics. Using its proprietary aibVIS platform, the company collaborates with pharmaceutical partners on mRNA-targeted small molecule drugs and is now independently developing mRNA-targeted nucleic acid drugs, with a strategic focus on addressing unmet medical needs, particularly in rare and ischemic organ diseases.
Average Trading Volume: 39,630
Technical Sentiment Signal: Sell
Current Market Cap: Yen2.98B
For detailed information about 130A stock, go to TipRanks’ Stock Analysis page.